Selective KDM small molecule inhibitors including KDM1A (LSD1) inhibitor ORY-1001 for acute lymphoblastic leukemia (ALL) and small-cell lung cancer, KDM4 inhibitor IOX1 for glioblastoma, KDM5 inhibitor CPI-455 for ALL, and KDM6 inhibitor GSK-J4 for various malignancies, are under clinical evaluation. This evidence concerns the gene KDM1A and small cell lung carcinoma.